High frequency of mosaic CREBBP deletions in Rubinstein-Taybi syndrome patients and mapping of somatic and germ-line breakpoints.

[1]  J. Kohlhase,et al.  Confirmation of EP300 gene mutations as a rare cause of Rubinstein–Taybi syndrome , 2007, European Journal of Human Genetics.

[2]  D. Birnbaum,et al.  New types of MYST3-CBP and CBP-MYST3 fusion transcripts in t(8;16)(p11;p13) acute myeloid leukemias. , 2007, Haematologica.

[3]  R. Hennekam,et al.  Genetic heterogeneity in Rubinstein–Taybi syndrome: delineation of the phenotype of the first patients carrying mutations in EP300 , 2007, Journal of Medical Genetics.

[4]  G. Neri,et al.  Rubinstein-Taybi Syndrome: spectrum of CREBBP mutations in Italian patients , 2006, BMC Medical Genetics.

[5]  T. Haaf,et al.  Evidence for a new contiguous gene syndrome, the chromosome 16p13.3 deletion syndrome alias severe Rubinstein–Taybi syndrome , 2006, Human Genetics.

[6]  R. Kosaki,et al.  Screening for partial deletions in the CREBBP gene in Rubinstein-Taybi syndrome patients using multiplex PCR/liquid chromatography. , 2006, Genetic testing.

[7]  E. Seemanová,et al.  DNA sequencing of CREBBP demonstrates mutations in 56% of patients with Rubinstein–Taybi syndrome (RSTS) and in another patient with incomplete RSTS , 2005, Human Genetics.

[8]  Johan T den Dunnen,et al.  Genetic heterogeneity in Rubinstein-Taybi syndrome: mutations in both the CBP and EP300 genes cause disease. , 2005, American journal of human genetics.

[9]  H. Kehrer-Sawatzki,et al.  Extensively high load of internal tumors determined by whole body MRI scanning in a patient with neurofibromatosis type 1 and a non-LCR-mediated 2-Mb deletion in 17q11.2 , 2005, Human Genetics.

[10]  R. Tenconi,et al.  Uncommon Alu-mediated NF1 microdeletion with a breakpoint inside the NF1 gene. , 2005, Genomics.

[11]  J. Rowley,et al.  Characterization of genomic breakpoints in MLL and CBP in leukemia patients with t(11;16) , 2004, Genes, chromosomes & cancer.

[12]  J. Esteve,et al.  Type I MOZ/CBP (MYST3/CREBBP) is the most common chimeric transcript in acute myeloid leukemia with t(8;16)(p11;p13) translocation , 2004, Genes, chromosomes & cancer.

[13]  D. Strunk,et al.  RT-PCR and FISH analysis of acute myeloid leukemia with t(8;16)(p11;p13) and chimeric MOZ and CBP transcripts: breakpoint cluster region and clinical implications , 2004, Leukemia.

[14]  R. Tenconi,et al.  Evidence for non-homologous end joining and non-allelic homologous recombination in atypical NF1 microdeletions , 2004, Human Genetics.

[15]  D. Lacombe,et al.  Analysis of CBP (CREBBP) gene deletions in Rubinstein‐Taybi syndrome patients using real‐time quantitative PCR , 2004, Human mutation.

[16]  R. Siebert,et al.  Screening 500 unselected neurofibromatosis 1 patients for deletions of the NF1 gene , 2004, Human mutation.

[17]  Jan-Fang Cheng,et al.  Fifty microdeletions among 112 cases of Sotos syndrome: Low copy repeats possibly mediate the common deletion , 2003, Human mutation.

[18]  M. Odero,et al.  t(10;16)(q22;p13) and MORF‐CREBBP fusion is a recurrent event in acute myeloid leukemia , 2003, Genes, chromosomes & cancer.

[19]  B. Johansson,et al.  Genomic characterization of MOZ/CBP and CBP/MOZ chimeras in acute myeloid leukemia suggests the involvement of a damage‐repair mechanism in the origin of the t(8;16)(p11;p13) , 2003, Genes, chromosomes & cancer.

[20]  C. Cruaud,et al.  Molecular analysis of the CBP gene in 60 patients with Rubinstein-Taybi syndrome , 2002, Journal of medical genetics.

[21]  H. Hameister,et al.  Molecular characterization and gene content of breakpoint boundaries in patients with neurofibromatosis type 1 with 17q11.2 microdeletions. , 2001, American journal of human genetics.

[22]  B. Johansson,et al.  Fusion of the MORF and CBP genes in acute myeloid leukemia with the t(10;16)(q22;p13). , 2001, Human molecular genetics.

[23]  P. Marynen,et al.  Unequal meiotic crossover: a frequent cause of NF1 microdeletions. , 2000, American journal of human genetics.

[24]  R. Hennekam,et al.  Rubinstein-Taybi syndrome caused by a De Novo reciprocal translocation t(2;16)(q36.3;p13.3). , 2000, American journal of medical genetics.

[25]  R. Hennekam,et al.  Diagnostic analysis of the Rubinstein-Taybi syndrome: five cosmids should be used for microdeletion detection and low number of protein truncating mutations , 2000, Journal of medical genetics.

[26]  M. Weaver,et al.  NF1 microdeletion breakpoints are clustered at flanking repetitive sequences. , 2000, Human molecular genetics.

[27]  S. Balcı,et al.  FISH studies in 45 patients with Rubinstein-Taybi syndrome: deletions associated with polysplenia, hypoplastic left heart and death in infancy , 1999, European Journal of Human Genetics.

[28]  L. Larizza,et al.  A rapid and simple method for the generation of locus-specific probes for fish analysis , 1999 .

[29]  D. Housman,et al.  MLL is fused to CBP, a histone acetyltransferase, in therapy-related acute myeloid leukemia with a t(11;16)(q23;p13.3). , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[30]  C. Disteche,et al.  The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB–binding protein , 1996, Nature Genetics.

[31]  Raoul C. M. Hennekam,et al.  Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP , 1995, Nature.

[32]  E. Mariman,et al.  Rubinstein-Taybi syndrome caused by submicroscopic deletions within 16p13.3. , 1993, American journal of human genetics.

[33]  N. Tommerup,et al.  Tentative assignment of a locus for Rubinstein-Taybi syndrome to 16p13.3 by a de novo reciprocal translocation, t(7;16)(q34;p13.3). , 1992, American journal of medical genetics.

[34]  D. Lacombe,et al.  Confirmation of assignment of a locus for Rubinstein-Taybi syndrome gene to 16p13.3. , 1992, American journal of medical genetics.

[35]  Y. Kuroki,et al.  Rubinstein-Taybi syndrome with de novo reciprocal translocation t(2;16)(p13.3;p13.3). , 1991, American journal of medical genetics.